Biodegradable polymer drug-eluting stent vs. contemporary durable polymer drug-eluting stents in patients with diabetes: a meta-analysis of randomized controlled trials

被引:8
|
作者
Bavishi, Chirag [1 ]
Chugh, Yashasvi [2 ,3 ]
Kimura, Takeshi [4 ]
Natsuaki, Masahiro [5 ]
Kaiser, Christoph [6 ]
Gordon, Paul [1 ]
Aronow, Herbert D. [1 ]
Abbott, Jinnette Dawn [1 ]
机构
[1] Rhode Isl Hosp, Lifespan Cardiovasc Inst, Providence, RI 02903 USA
[2] Mt Sinai St Lukes Hosp, New York, NY USA
[3] Mt Sinai West Hosp, New York, NY USA
[4] Kyoto Univ, Grad Sch Med, Sakyo Ku, Kyoto, Japan
[5] Saga Univ, Saga, Japan
[6] Univ Hosp, Basel, Switzerland
关键词
Biodegradable polymer; Durable polymer; Drug-eluting stent; Diabetes; EVEROLIMUS; SAFETY; THROMBOSIS; OUTCOMES; EFFICACY; LEADERS;
D O I
10.1093/ehjqcco/qcz031
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims The biodegradable polymer drug-eluting stents (BP-DES) offer controlled drug elution and complete degradation of the polymer over time, eventually lowering the risk for chronic inflammation and neoatherosclerosis, which can be particularly helpful in patients with diabetes. While BP-DES and durable polymer drug-eluting stents (DP-DES) have demonstrated comparable efficacy in all-comers population, their efficacy and safety in patients with diabetes remains uncertain. Methods and results Electronic databases were systematically searched for randomized controlled trials (RCTs) comparing BP-DES with contemporary DP-DES in patients with diabetes. Study investigators were contacted to obtain additional data. The primary outcome was efficacy in terms of target-vessel revascularization (TVR) and target-lesion revascularization (TLR). We also evaluated the following safety outcomes separately: all-cause mortality, cardiac mortality, myocardial infarction (MI), and definite or probable stent thrombosis. Eleven RCTs including 5190 diabetic patients were included. At the longest available follow-up (mean 2.7 years), there was no significant difference in TLR [relative risk (RR): 1.02, 95% confidence interval (CI): 0.85-1.24; P = 0.80] or TVR (RR: 1.04, 95% CI: 0.81-1.34; P = 0.76). Safety outcomes of all-cause mortality, cardiac mortality, and MI were similar between the two groups. Stent thrombosis rates were also similar between BP-DES and DP-DES groups (1.66% vs. 1.83%; RR: 0.84, 95% CI: 0.54-1.31; P = 0.45). The heterogeneity was low and fixed-effect model yielded similar results. Meta-regression analysis showed no relationship between insulin requiring diabetes and difference in TLR or stent thrombosis between BP-DES and DP-DES. Conclusion Overall, BP-DESs have similar safety and efficacy profiles compared to contemporary DP-DES in patients with diabetes.
引用
收藏
页码:81 / 88
页数:8
相关论文
共 50 条
  • [21] Comparison of the biodegradable polymer everolimus-eluting stent with contemporary drug-eluting stents: A systematic review and meta-analysis
    Picard, Fabien
    Pighi, Michele
    de Hemptinne, Quentin
    Airaksinen, Juhani
    Vinco, Giulia
    de Pommereau, Aurelien
    Biancari, Fausto
    Varenne, Olivier
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2019, 278 : 51 - 56
  • [22] A META-ANALYSIS OF RANDOMIZED TRIALS COMPARING LONG-TERM (5-YEAR) SAFETY AND EFFICACY OF BIODEGRADABLE POLYMER DRUG-ELUTING STENTS WITH NEW GENERATION DURABLE POLYMER DRUG-ELUTING STENTS
    Najib, Khalid
    Ashraf, Farhan
    Khan, Babar
    Rawal, Aranyak
    Shah, Rahman
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 1064 - 1064
  • [23] Safety and Efficacy of Polymer Free vs. Based Drug-eluting Stents A Meta-Analysis of Randomized Trials
    Zhao Xiaohui
    Huang Lan
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (16) : C85 - C85
  • [24] Ultrathin-strut biodegradable polymer versus durable polymer drug-eluting stents: a meta-analysis
    Monjur, Mohammad Riashad
    Said, Christian F.
    Bamford, Paul
    Parkinson, Michael
    Szirt, Richard
    Ford, Thomas
    OPEN HEART, 2020, 7 (02):
  • [25] Polymer-free drug-eluting stents versus permanent polymer drug-eluting stents An updated meta-analysis
    Chen, Yun-lin
    Fan, Jinqi
    Chen, Guozhu
    Cao, Li
    Lu, Li
    Xu, Yanping
    Yin, Yuehui
    MEDICINE, 2019, 98 (15)
  • [26] Adverse cardiovascular events associated with biodegradable polymer drug-eluting stents and durable polymer everolimus-eluting stents A systematic review and meta-analysis of 10 randomized controlled trials
    Bundhun, Pravesh Kumar
    Janoo, Girish
    Yanamala, Chandra Mouli
    Huang, Feng
    MEDICINE, 2017, 96 (28)
  • [27] Biodegradable-Polymer vs. Durable-Polymer Drug-Eluting Stents in Patients With Acute Myocardial Infarction
    Rha, Seung-Woon
    Mashaly, Ahmed
    Choi, Byoung Geol
    Choi, Se Yeon
    Byun, Jae Kyeong
    Abdelshafi, Kareem
    Park, Yoonjee
    Kang, Dong Oh
    Jang, Won Young
    Kim, WooHyeun
    Park, Eun Jin
    Na, Jin Oh
    Choi, Cheol Ung
    Kim, Eung Ju
    Park, Chang Gyu
    Seo, Hong Seog
    JACC-CARDIOVASCULAR INTERVENTIONS, 2019, 12 (04) : S7 - S7
  • [28] The impact of biodegradable versus durable polymer drug-eluting stents on stent thrombosis in patients with coronary artery disease: a meta-analysis of 15 randomized trials
    Zhang, Yao-Jun
    Iqbal, Javaid
    Bourantas, Christos
    Chen, Shao Liang
    Garcia-Garcia, Hector
    Muramatsu, Takashi
    Serruys, Patrick W.
    Dong Sheng-Jie
    Xu, Bo
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (18) : B252 - B252
  • [29] Letter on "Comparison of the biodegradable polymer everolimus-eluting stent with contemporary drug-eluting stents: A systematic review and meta-analysis"
    Pan, Xiaoping
    Li, Xiaofei
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 337 : 53 - 53
  • [30] Comparison of biodegradable and durable polymer drug-eluting stents in acute coronary syndrome: a meta-analysis
    Yuan, Haoyong
    Wu, Zhongshi
    Lu, Ting
    Wei, Tingting
    Zeng, Yifan
    Liu, Yalin
    Huang, Can
    BMJ OPEN, 2022, 12 (06):